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Background: Racial disparities in breast cancer survival have been well documented. This study examines the
association of race/ethnicity and socioeconomic status (SES) on breast cancer-specific mortality in a large
population of women with invasive breast cancer.
Methods: We identified 179,143 cases of stages 1–3 first primary female invasive breast cancer from the California
Cancer Registry from January, 2000 through December, 2010. Cox regression, adjusted for age, year of diagnosis,
grade, and ER/PR/HER2 subtype, was used to assess the association of race/ethnicity on breast cancer-specific
mortality within strata of stage and SES. Hazard ratios (HR) and 95% confidence intervals were reported.
Results: Stage 1: There was no increased risk of mortality for any race/ethnicity when compared with whites within
all SES strata. Stage 2: Hispanics (HR = 0.85; 0.75, 0.97) in the lowest SES category had a reduced risk of mortality..
Blacks had the same risk of mortality as whites in the lowest SES category but an increased risk of mortality in the
intermediate (HR = 1.66; 1.34, 2.06) and highest (HR = 1.41; 1.15, 1.73) SES categories. Stage 3: Hispanics (HR = 0.74;
0.64, 0.85) and APIs (HR = 0.64; 0.50, 0.82) in the lowest SES category had a reduced risk while blacks had similar
mortality as whites. Blacks had an increased risk of mortality in the intermediate (HR = 1.52; 1.20, 1.92) and highest
(HR = 1.53; 1.22, 1.92) SES categories.
Conclusions: When analysis of breast cancer-specific mortality is adjusted for age and year of diagnosis, ER/PR/HER2
subtype, and tumor grade and cases compared within stage and SES strata, much of the black/white disparity
disappears. SES plays a prominent role in breast cancer-specific mortality but it does not fully explain the racial/ethnic
disparities and continued research in genetic, societal, and lifestyle factors is warranted.
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Breast cancer is the most common cancer in women resid-
ing in California, regardless of age or race/ethnicity [1-3]
but the burden of this cancer has an unequal racial/ethnic
distribution. Racial disparities in breast cancer incidence
and mortality have been well documented in the past, par-
ticularly among African American women, who have been
found to have a lower incidence of breast cancer compared
to white women, but a higher overall mortality [4,5].
A wealth of studies have documented the many factors
specifically associated with disparities of cancer care such* Correspondence: parisec@sutterhealth.org
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distribution, and reproduction in any mediumas age, race/ethnicity, socioeconomic status (SES), access
to health care, cultural, medical, and health provider issues
[6-18]. Additionally, prognostic factors directly related to
breast cancer including tumor size, histology, grade, nodal
and receptor status, and stage at diagnosis are expressed
differentially in the population by age and race/ethnicity
[19-23] adding further complexity to any discussion of dis-
parities in cancer care.
Over 40 years ago, the California Cancer Registry
(CCR) noted that breast cancer patients treated at private
hospitals survived their cancer better than patients treated
in public hospitals [24]. Expanding on this early attempt
to explain how social class or SES relates to breast cancer
survival, the objective of this present investigation is toCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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cancer survival persists when analyses are conducted that
compare patients within the same SES category and stage
at diagnosis.
Methods
Using the population-based CCR, we identified cases of
American Joint Commission on Cancer (AJCC) stages
1–3 first primary female invasive breast cancer (ICDO-3
sites C50.0-C50.9) [25] diagnosed between January 1,
2000 through December 31, 2010 and reported to the
CCR as of January, 2012. Cases are reported to the Cancer
Surveillance Section of the California Department of Public
Health from hospitals and any other facilities providing
care or therapy to cancer patients residing in California
[26]. Cases identified outside of California, only at autopsy,
or from death certificates were excluded. Breast cancer-
specific mortality was defined as a death due to breast can-
cer as documented by the codes ranging from C50.01 to
C50.91 of the International Statistical Classification of Dis-
eases and Related Health Problems, 10th Revision. Deaths
due to causes other than cancer were censored.
SES
Quintile of SES was derived using data from the 2000 U.
S. census. SES was assigned at the census block group
level and based on address at time of initial diagnosis, as
reported in the medical record. This area based compos-
ite SES measure was created through principal compo-
nents analysis [27] and included the following census
variables: proportion with a blue-collar job, propor-
tion older than 16 years without a job, median household
income, population living below 200% Federal Poverty
Level, median gross rent, median value of owner-occupied
houses, and a median education index [28]. Quintiles of
SES ranging from 1 (the lowest/ least affluent) to 5 (the
highest/most affluent) were computed. This area based
SES measure has been used in many studies utilizing can-
cer registry data [22,29-33]. A detailed description of this
methodology is found in other publications [34].
For ease of presentation, in this study, we combined
the lowest two quintiles 1 + 2 (lowest/least affluent) as
well as the highest two quintiles 4 + 5 (highest/most af-
fluent).The intermediate (3) remained intact.
Race/ethnicity
Race/ethnicity was classified into six distinct categories:
White, African American or black, Hispanic, Asian-
Pacific Islander (API), American Indian, and Hispanic
plus other race. The race/ethnicity information contained
in the medical record was obtained by patient self-
identification, assumptions based on personal appearance,
or inferences based on the race/ethnicity of the parents,
birthplace, surname, or maiden name. The API categorywas derived from combining cases identified as Pacific
Islander, Southeast Asian, Indian continent, Chinese,
Japanese, Filipino, and Korean.
Determination of Hispanic ethnicity was based on in-
formation from the medical record and computer-based
comparisons to the 1980 U.S. census list of Hispanic sur-
names. Patients identified as Hispanic on the medical
record as white with a Hispanic surname were classified
as Hispanic. Cases identified as black or API and also
identified as Hispanic were categorized as Hispanic plus
other race. This classification resulted in six mutually ex-
clusive categories: White, black, Hispanic, API, American
Indian, and Hispanic plus other race.
ER/PR/HER2
The details of documentation of estrogen receptor (ER)
progesterone receptor (PR), and human epidermal growth
factor receptor 2 (HER2) along with age and stage at diag-
nosis, and tumor grade have been extensively described in
our previous publications [22,32,35,36]. And by the CCR
[26]. Age was grouped into five categories (<35, 35–69,
70–79, 80–89, and 90+ years). Year of diagnosis was
categorized as 2000–2006 and 2007–2010. The year
2007 marks the first complete year following approval
of trastuzumab for adjuvant therapy for breast cancer.
Statistical analysis
The number of cases with missing data for ER, PR,
HER2, race, grade, cause of death, and survival time
were computed. Contingency tables were used to as-
sess the distribution of missing data by race, and the
distribution of demographic and tumor characteristics
among SES strata.
Cox proportional hazards modeling was used to deter-
mine time from breast cancer diagnosis to time of breast
cancer-specific death for African Americans, Hispanics,
and APIs, when compared with whites. All analyses were
conducted separately for each stage because of the dif-
ferences in prognosis of patients diagnosed in different
stages. Separate models with and without SES were run
to test whether SES confounded the association of race
with mortality. The interaction between race and SES
was then tested to determine if the affect of race on
mortality varied among the levels of SES.
Analyses were stratified by both stage and SES so that
the risk of mortality for each race could be estimated for
cases within each stage/SES stratum.
All models were adjusted for age, ER/PR/HER2, grade,
and year of diagnosis. Hazard ratios (HR) and 95% Con-
fidence Intervals (CIs) were computed for all models.
The HR represents the estimated risk of mortality for
two people of the same age and tumor characteristic
when one person is black, Hispanic, or API, and the other
person is white.
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from the California Cancer Registry without subject inter-
vention. No identifiers were linked to subjects. Therefore,
the study was approved by Sutter Health Central Institu-
tional Review Committee under the category “exempt”.
Results
Missing data
The initial data contained 181,090 cases of stages 1–3
first primary invasive breast cancer. Cases where race
was identified as American Indian (n = 275), Hispanic
plus other race (n = 517), or race unknown (n = 1,155)
were excluded, which resulted in 179,143 cases with
complete data for year of diagnosis, age, race/ethnicity,
stage, vital status, and SES. Tumor grade, ER/PR/HER2
status, and unknown cause of death were missing for
57,695 cases leaving 123,395 cases with complete data
(Table 1).
The distribution of missing ER, PR and HER2 was
similar for all race/ethnicities ranging from 8.2% to
9.8% for ER; 10.9% to 12.6% for PR and 24.4% to 25.9%
for HER2. There was little variation among the race/
ethnicities for missing grade, ranging from 5.5% to 6.0%.
Cause of death was missing equally among all races (1.2%
to 1.5%).
Demographics and tumor characteristics
Table 2 shows the distribution of cases within each of
the SES categories. There was no appreciable difference
in the year of diagnosis among all SES categories. Of the
patients within the lowest SES category, 50.2% were
white, 10.9% were black, 29.8% were Hispanic, and 9.1%
were API. In contrast, within the highest SES category,
the percents were 76.1%, 3.1%, 8.4%, and 12.4% respect-
ively. Over 50% of African Americans and Hispanics
were in the lowest and intermediate SES categories.Table 1 Summary of missing data for incident female
stages 1–3 invasive breast cancer reported to the California
Cancer Registry 2000–2010 with complete data for age,






Tumor grade 10,594 (5.9%)
Unknown cause of death 2,386 (1.5%)
Total cases with one or more of the
above variables missing†
57,695 (31.9%)
Total cases with complete data 123,395 (68.1%)
*HER2 data not easily retrievable in the registry until 2006.
†Cases may be missing data for more than one variable.The relationship between stage and SES was inform-
ative. For patients in the lowest SES category, 43.7% were
stage 1, whereas 51.7% of patients within the highest SES
category had stage 1 disease. For stages 2 and 3, with
each increase in an SES category a decrease in the per-
cent of patients was noted.
A significantly higher percent of patients within the
lowest SES category had the ER-/PR-HER2- and ER-/PR-
HER2+ subtypes when compared with the highest SES
category (Table 2).
The distribution of cases by race/ethnicity is shown in
Table 3. The majority of white (58.2%) and API patients
(57.9%) were in the highest SES category. In contrast,
the majority of black (51.3%) and Hispanic patients
(52.3%) were in the lowest SES category. Of the 3,688
patients under 35 years of age, 1,600 (43.4%) were white
and 1,215 (32.9%) were Hispanic. However, only 1.3% of
white patients were less than 35 years of age, whereas
4.3% of Hispanic patients were in that age group. With
each increasing age category, the percent of whites diag-
nosed increased progressively while the percent of all
other races decreased. Over 80% of women aged 80 and
older were white.
The ER+/PR+/HER2- subtype was the most common
(57.2%), but variation by race/ethnicity was noted, espe-
cially between white (60.3%) and black patients (42.9%).
Black and Hispanic patients had the highest percent of
the triple-negative subtype, 25.5% and 16.3%, respect-
ively. Whites had the lowest percent of patients among
the four HER2-positive subtypes. This was especially no-
ticeable within the ER-/PR-/HER2+ subtype, the molecu-
larly defined HER2-overexpressing subtype, with whites
having the lowest (5.5%) and API patients the highest
(9.3%) percent.
The majority of white patients (52.1%) presented in
stage 1, compared with approximately 40% of both black
and Hispanic patients presenting in this stage. A higher
percent of black (15.9%) and Hispanic (15.7%) patients
presented with stage 3 disease compared with white
(9.9%) and API (10.7%) patients. Over 60% of white
patients presented with the ER+/PR +HER2- subtype.
Among black patients, 25.5% had ER-/PR-HER2- com-
pared with only 11.3% of whites. African Americans,
Hispanics, and API patients were diagnosed at a higher
grade (Table 3).
Cox proportional hazards
Cox proportional hazards models adjusted for age, ER/
PR/HER2, grade, and year of diagnosis indicated that in-
clusion of SES was a confounder of the association of
race with breast cancer-specific mortality (results not
shown). SES reduced the effect of all race/ethnicities on
mortality in all stages. The strength of the effect of SES
was strongest for blacks in stage 1 where the HR was
Table 2 Distribution of demographic and tumor characteristics of stages 1–3 first primary invasive breast cancer by
socioeconomic status: California Cancer Registry 2000–2010*
Socioeconomic status category
Lowest/least affluent Intermediate Highest/most affluent Total
N (%) 49,868 (27.8%) 37,128 (20.7%) 92,147 (51.36%) 179,143
Year at diagnosis
2000-2006
n 31,380 23,844 59,359 114,583
% within SES 62.9% 64.2% 64.4% 64.0%
2007-2010
n 18,488 13,284 32,788 64,560
% within SES 37.1% 35.8% 35.6% 36.0%
Race/ethnicity
White
n 25,016 25,283 70,136 120,435
% within SES 50.2% 68.1% 76.1% 67.2%
Black
n 5,454 2,349 2,834 10,637
% within SES 10.9% 6.3% 3.1% 5.9%
Hispanic
n 14,848 5,756 7,776 28,380
% within SES 29.8% 15.5% 8.4% 15.8%
API
n 4,550 3,740 11,401 19,691
% within SES 9.1% 10.1% 12.4% 11.0%
Age (years) at diagnosis
<35
n 1,347 713 1,628 3,688
% within SES 2.7% 1.9% 1.8% 2.1%
35-69
n 35,557 25,924 66,589 128,070
% within SES 71.3% 69.8% 72.3% 71.5%
70-79
n 8,414 6,708 15,388 30,510
% within SES 16.9% 18.1% 16.7% 17.0%
80-89
n 4,022 3,349 7,565 14,936
% within SES 8.1% 9.0% 8.2% 8.3%
90+
n 528 434 977 1,939
% within SES 1.1% 1.2% 1.1% 1.1%
AJCC stage
Stage 1
n 21,814 18,066 47,655 87,535
% within SES 43.7% 48.7% 51.7% 48.9%
Stage 2
n 21,082 14,776 35,550 71,408
% within SES 42.3% 39.8% 38.6% 39.9%
Stage 3
n 6,972 4,286 8,942 20,200
% within SES 14.0% 11.5% 9.7% 11.3%
ER/PR/HER2 subtype
ER+/PR+/HER2-
n 18,434 15,088 40,900 74,422
% within SES 52.6% 56.6% 59.8% 57.2%
ER+/PR+/HER2+
n 3,521 2,519 6,204 12,244
% within SES 10.0% 9.5% 9.1% 9.4%
ER+/PR-/HER2-
n 3,264 2,548 6,702 12,514
% within SES 9.3% 9.6% 9.8% 9.6%
ER+/PR-/HER2+
n 1,180 856 2,082 4,118
% within SES 3.4% 3.2% 3.0% 3.2%
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Table 2 Distribution of demographic and tumor characteristics of stages 1–3 first primary invasive breast cancer by
socioeconomic status: California Cancer Registry 2000–2010* (Continued)
ER-/PR+/HER2-
n 285 212 527 1,024
% within SES 0.8% 0.8% 0.8% 0.8%
ER-/PR+/HER2+
n 167 120 226 513
% within SES 0.5% 0.5% 0.3% 0.4%
ER-/PR-/HER2-
n 5,454 3,550 7,821 16,825
% within SES 15.6% 13.3% 11.4% 100.0%
ER-/PR-/HER2+ n 2,744 1,753 3,941 12.9%
% within SES 7.8% 6.6% 5.8% 8,438
Tumor grade n 9,276 7,998 22,058 39,332
Grade I
% within SES 19.9% 22.9% 25.3% 23.3%
n 18,814 14,625 37,837 71,276
Grade II
% within SES 40.3% 41.9% 43.4% 42.3%
n 17,586 11,572 25,888 55,046
Grade III
% within SES 37.7% 33.2% 29.7% 32.6%
n 1,001 698 1,344 3,043
Grade IV % within SES 2.1% 2.0% 1.5% 1.8%
*Excludes cases classified as American Indian and Hispanic + Other race.
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SES to 1.19 when included. The models that included
the interaction between SES and race/ethnicity were sta-
tistically significant for stages 2 and 3 (p < 0.05) which
indicated that the association of race with mortality
was not the same for all levels of SES. Therefore models
stratified by both stage and SES were more appropriate
and these results are presented in Table 4.
Table 4 shows that in stage 1 there was no increased
risk of mortality for any race/ethnicity when compared
with whites for all SES categories. In stage 2, Hispanics
had a 15% reduced risk of mortality in the lowest SES
category. Blacks had the same risk of mortality as whites
in lowest SES category. However, in the intermediate
and highest SES categories, blacks had a statistically sig-
nificantly higher risk of mortality.
For stage 3, in the lowest SES category, Hispanics and
APIs had a reduced risk of mortality while blacks had
similar mortality as whites. In the intermediate SES cat-
egory, blacks had a 52% increased risk of mortality and a
53% increased risk in the highest SES category.
For all stages, there was no black/white disparity in
the lowest SES category. However, Hispanics in the low-
est SES had better survival than whites in stages 2 and 3.
Discussion
Racial disparities in breast cancer treatment and outcomes
have been previously well documented [2,8,37,38]. Survival
differences between African American and white patients
with breast cancer have often been attributed to more ad-
vanced stage at diagnosis [39], unfavorable tumor biologyfeatures such as hormone receptor-negative disease [19] or
triple-negative disease [40], lower SES [5,41], and inferior
use of adjuvant treatments [9,42-46].
It remains difficult to completely separate and untan-
gle the interplay among race/ethnicity, SES, and tumor
biology, and determine their respective roles in breast
cancer outcomes. This dilemma is evident from the
conflicting results of studies investigating racial/ethnic
disparities in cancer. Some have shown comparable out-
comes after adjustment for sociodemographic factors if
patients have equal access to healthcare [47-52]. Others
have found that low SES, not race, was associated with
poorer outcomes [41,53,54].
Further, some studies have shown racial disparities
even after adjusting for SES. In a meta-analysis of 20
studies representing a total of 14,013 African Americans
and 76,111 white American women diagnosed with
breast cancer from 1961 to 2003, Newman concluded
that African American ethnicity is a significant and inde-
pendent predictor of poor outcome from breast cancer,
even after accounting for SES [55]. Also, a Southwest
Oncology Group study concluded that, after adjustment
for SES, African American patients with breast cancer
had worse adjusted survival, despite enrollment on phase
III clinical trials with uniform stage, treatment, and
follow-up [56]. These latter studies, as well as others
[57-59] suggest biologic differences in tumor behavior as
the reason for racial/ethnic disparities.
Others argue against a biologic hypothesis for racial
disparities. In a study of breast cancer-specific mortality
rates for women in Chicago, New York City, and the
Table 3 Distribution of demographic and tumor characteristics of stages 1–3 first primary invasive breast cancer by
race/ethnicity: California Cancer Registry 2000–2010*
Race/Ethnicity
White Black Hispanic API Total
N (%) 120,435 (67.2%) 10,637 (5.9%) 28,380 (15.8%) 19,691 (11.1%) 179,143
Year at diagnosis
n 79,226 6,662 17,054 11,641 114,583
2000-2006 % within race/ethnicity 65.8% 62.6% 60.1% 59.1% 64.0%
n 41,209 3,975 11,326 8,050 64,560
2007-2010 % within race/ethnicity 34.2% 37.4% 39.9% 40.9% 36.0%
Socioeconomic status
n 25,016 5,454 14,848 4,550 49,868
Lowest/Least Affluent % within race/ethnicity 20.8% 51.3% 52.3% 23.1% 27.8%
n 25,283 2,349 5,756 3,740 37,128
Intermediate % within race/ethnicity 21.0% 22.1% 20.3% 19.0% 20.7%
n 70,136 2,834 7,776 11,401 92,147
Highest/Most Affluent % within race/ethnicity 58.2% 26.6% 27.4% 57.9% 51.4%
Age at diagnosis (years)
n 1,600 299 1,215 574 3,688
<35 % within race/ethnicity 1.3% 2.8% 4.3% 2.9% 2.1%
n 81,900 8,055 22,331 15,784 128,070
35-69 % within race/ethnicity 68.0% 75.7% 78.7% 80.2% 71.5%
n 23,132 1,518 3,466 2,394 30,510
70-79 % within race/ethnicity 19.2% 14.3% 12.2% 12.2% 17.0%
n 12,223 672 1,190 851 14,936
80-89 % within race/ethnicity 10.1% 6.3% 4.2% 4.3% 8.3%
n 1,580 93 178 88 1,939
90+ % within race/ethnicity 1.3% 0.9% 0.6% 0.4% 1.1%
AJCC stage n 62,693 4,195 11,321 9,326 87,535
Stage 1 % within race/ethnicity 52.1% 39.4% 39.9% 47.4% 48.9%
n 45,791 4,751 12,608 8,258 71,408
Stage 2 % within race/ethnicity 38.0% 44.7% 44.4% 41.9% 39.9%
n 11,951 1,691 4,451 2,107 20,200
Stage 3 % within race/ethnicity 9.9% 15.9% 15.7% 10.7% 11.3%
ER/PR/HER2 subtype
n 52,797 3,240 10,526 7,859 74,422
ER+/PR+/HER2- % within race/ethnicity 60.3% 42.9% 51.0% 54.9% 57.2%
n 7,689 709 2,181 1,665 12,244
ER+/PR+/HER2+ % within race/ethnicity 8.8% 9.4% 10.6% 11.6% 9.4%
n 8,791 735 1,816 1,172 12,514
ER+/PR-/HER2- % within race/ethnicity 10.0% 9.7% 8.8% 8.2% 9.6%
n 2,675 252 678 513 4,118
ER+/PR-/HER2+ % within race/ethnicity 3.1% 3.3% 3.3% 3.6% 3.2%
n 640 77 194 113 1,024
ER-/PR+/HER2- % within race/ethnicity 0.7% 1.0% 0.9% 0.8% 0.8%
n 281 45 126 61 513
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Table 3 Distribution of demographic and tumor characteristics of stages 1–3 first primary invasive breast cancer by
race/ethnicity: California Cancer Registry 2000–2010* (Continued)
ER-/PR+/HER2+ % within race/ethnicity 0.3% 0.6% 0.6% 0.4% 0.4%
n 9,924 1,929 3,371 1,601 16,825
ER-/PR-/HER2- % within race/ethnicity 11.3% 25.5% 16.3% 11.2% 12.9%
n 4,789 572 1,748 1,329 8,438
ER-/PR-/HER2+ % within race/ethnicity 5.5% 7.6% 8.5% 9.3% 6.5%
Tumor grade n 29,749 1,516 4,613 3,454 39,332
Grade I % within race/ethnicity 26.2% 15.1% 17.3% 18.6% 23.3%
n 49,124 3,570 10,610 7,972 71,276
Grade II % within race/ethnicity 43.3% 35.5% 39.8% 43.0% 42.3%
n 32,747 4,691 10,823 6,785 55,046
Grade III % within race/ethnicity 28.9% 46.7% 40.6% 36.6% 32.6%
n 1,802 276 620 345 3,043
Grade IV % within race/ethnicity 1.6% 2.7% 2.3% 1.9% 1.8%
*Excludes cases classified as American Indian and Hispanic + Other race.
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were used to measure the disparity in breast cancer-
specific mortality. In all three locations the black and
white rates were similar in the 1980s and remained that
way until the 1990s, when the white rates started to de-
cline while the black rates remained constant, just as the
benefits from early detection by mammography and from
treatment were noticeable [60-62]. These findings seem
to argue against differential tumor biology.
The goal of our present study was to assess racial/eth-
nic disparities within three levels of SES and within the
same stage of disease so that variability among treatment
and access to care would be minimized. We also ad-
justed for ER/PR/HER2 because of the known propensity
of African American and Hispanic women to have hor-
mone receptor-negative and, in particular, triple-negative
phenotype [16,19,22,40].
The present investigation has shown that for women
with stage 1 breast cancer, there is no disparity among
any race/ethnicity regardless of the SES category. In
addition, there is no black/white disparity within the
lowest SES category regardless of stage of disease, but a
disparity is apparent in the higher SES categories. African
Americans in the intermediate and highest SES categories
with stages 2 and 3 breast cancer have increased risk of
mortality when compared with whites. Interestingly, low
SES Hispanic patients with stages 2 and 3 disease have
a lower risk of mortality when compared to low SES
white patients, similar to what has been described in the
“Hispanic Paradox” [63].
As is often the case, a correlational study raises more
questions than answers. On the one hand, a differential
tumor or host biology does not seem to be plausible be-
cause there were no differences in risk of mortality amongany race/ethnicity in stage 1 and there was no black/
white disparity for women in the lowest SES category
regardless of stage. On the other hand, for higher stages
of disease, black patients in the same, higher SES cat-
egory had an increased risk of mortality as compared to
white patients while Hispanics in the lowest SES cat-
egory at higher stages had decreased risk of mortality as
did APIs in Stage 3.
The findings of this study raise the question of whether
tumor or host factors play a role in advanced stages of dis-
ease. Do black, white, Hispanic, and API patients respond
differentially to treatments? Data regarding racial/ethnic
differences in the pharmcogenomics of chemotherapy and
endocrine response and toxicities are limited [64-66]. Al-
ternatively, are more aggressive treatments offered or avail-
able to patients of all race/ethnicities even when there
is presumed equal access to care? Is there an element of
racial/ethnic discrimination in receipt of more aggressive
cancer treatments [62,67,68]?
The results of this population-based registry study
cannot definitively answer these perplexing questions,
but at least in stage 1 disease, a differential tumor biol-
ogy appears unlikely. It also appears that SES plays a
prominent role in cancer outcomes although genetic, en-
vironmental, societal, lifestyle, and health provider fac-
tors may also contribute to racial disparities, and they
should not be overlooked [69].
The limitations of population-based cancer registry in-
vestigations including exclusion of subjects without ER,
PR, and HER2 are well known [22,32,45,70-72]. Accurate
and precise treatment information was not available
from the registry. Although it has been suggested that
suboptimal use of adjuvant treatments may explain differ-
ences in outcomes, [9,42-46] others have reported little or
Table 4 Hazard ratios and 95% confidence intervals
derived from Cox regression for race/ethnicity after
adjustment for age, year of diagnosis, grade, and
ER/PR/HER2 subtype*
Stage 1 HR (95% CI)
SES
Lowest/least affluent (n = 14,011)
White 1.00
Black 1.19 (0.85, 1.65)
Hispanic 0.96 (0.74, 1.13)
API 0.69 (0.43, 1.11)
Intermediate (n = 11,839)
White 1.00
Black 0.88 (0.51, 1.54)
Hispanic 0.93 (0.64, 1.36)
API 0.92 (0.59, 1.43)
Highest/most affluent (n = 32,945)
White 1.00
Black 1.47 (0.96, 2.27)
Hispanic 1.05 (0.76, 1.44)





Black 1.14 (0.97, 1.38)
Hispanic 0.85 (0.75, 0.97)
API 0.85 (0.69, 1.04)
Intermediate (10,141)
White 1.00
Black 1.66 (1.34, 2.06)
Hispanic 1.11 (0.92, 1.32)
API 0.80 (0.62, 1.03)
Highest/most affluent (25,323)
White 1.00
Black 1.41 (1.15, 1.73)
Hispanic 1.12 (0.95, 1.31)





Black 1.05 (0.88, 1.25)
Hispanic 0.74 (0.64, 0.85)
API 0.64 (0.50, 0.83)
Intermediate (3,087)
White 1.00
Table 4 Hazard ratios and 95% confidence intervals
derived from Cox regression for race/ethnicity after
adjustment for age, year of diagnosis, grade, and
ER/PR/HER2 subtype* (Continued)
Black 1.52 (1.20, 1.92)
Hispanic 1.12 (0.91, 1.37)
API 0.92 (0.69, 1.23)
Highest/most affluent (6,532)
White 1.00
Black 1.53 (1.22, 1.92)
Hispanic 0.97 (0.79, 1.17)
API 0.92 (0.76, 1.11)
*Confidence intervals that include 1.00 indicate that the risk of mortality for a
race/ethnicity was not statistically significantly better or worse than for whites
within a stage/SES stratum.
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gard to chemotherapy administration [73-75]. Differences
in adjuvant treatment between black and white women
may explain the disparities we noted in stages 2 and 3
[76,77]. However, since the disparities occurred only in the
two highest SES categories, we can speculate that patients
of all race/ethnicities should have had equal access to adju-
vant treatment.
We recognize that determination of race/ethnicity can
be problematic and arbitrary. Hispanic ethnicity may in-
clude women from Mexico, Central and South America,
Spain, as well as Puerto Rico and Cuba. The category
API may include women from Asia, the Indian Continent,
and the Pacific Islands. We also recognize that our meas-
ure of SES was at the neighborhood level rather than
at the individual level. The CCR does not obtain the
information necessary to determine individual SES but
others have commented on the usefulness of composite
SES measures [78,79] In addition, this measure of SES
has been used in many studies that utilize cancer registry
data [22,29-33].
Lastly, other than age, we have no information about
reproductive history and lifestyle risk factors such as
nulliparity, multiparity, breast feeding, diet, body fat distri-
bution, use of alcohol, oral contraceptives, or hormone re-
placement treatments that may determine the type of
breast cancer and ultimately impact survival, [80-88].
Despite these shortcomings, our study is unique because
of the large number of cases reported to the statewide can-
cer registry from an ethnically diverse population. Unlike
other studies that employed different methodologies
of SES [55] or had extensive missing SES information
[56,89,90], we used a validated measure of SES for all
179,143 patients and most importantly, we stratified by
both stage and SES to minimize the potential that our re-
sults would be due to differences either in severity of dis-
ease or access to care.
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http://www.biomedcentral.com/1471-2407/13/449Conclusions
Our research has shown that when breast cancer-
specific mortality is analyzed either by race/ethnicity or
by SES, significant differences exist among the races
with respect to age at presentation, stage at diagnosis,
ER/PR/HER2 subtype, and tumor grade. However, when
adjusting analyses for these variables and comparing
cases within stage and SES strata, much of the black/
white disparity disappears.
SES plays a prominent role in breast cancer-specific
mortality but it does not fully explain the racial/ethnic
disparities and continued research in genetic, societal,
and lifestyle factors is warranted.
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